- Home
- INCY vs WLK Comparison
INCY vs WLK Comparison
Compare INCY & WLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- WLK
- Stock Information
- Founded
- INCY 1991
- WLK 1986
- Country
- INCY United States
- WLK United States
- Employees
- INCY N/A
- WLK N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- WLK Major Chemicals
- Sector
- INCY Health Care
- WLK Industrials
- Exchange
- INCY Nasdaq
- WLK Nasdaq
- Market Cap
- INCY 13.4B
- WLK 13.8B
- IPO Year
- INCY 1993
- WLK 2004
- Fundamental
- Price
- INCY $58.21
- WLK $91.85
- Analyst Decision
- INCY Hold
- WLK Buy
- Analyst Count
- INCY 20
- WLK 13
- Target Price
- INCY $74.00
- WLK $126.08
- AVG Volume (30 Days)
- INCY 2.3M
- WLK 939.2K
- Earning Date
- INCY 04-29-2025
- WLK 05-02-2025
- Dividend Yield
- INCY N/A
- WLK 2.28%
- EPS Growth
- INCY N/A
- WLK 25.41
- EPS
- INCY 0.15
- WLK 4.64
- Revenue
- INCY $4,241,216,999.00
- WLK $12,142,000,000.00
- Revenue This Year
- INCY $12.21
- WLK $3.08
- Revenue Next Year
- INCY $9.20
- WLK $6.05
- P/E Ratio
- INCY $345.39
- WLK $19.80
- Revenue Growth
- INCY 14.76
- WLK N/A
- 52 Week Low
- INCY $50.35
- WLK $81.41
- 52 Week High
- INCY $83.95
- WLK $161.31
- Technical
- Relative Strength Index (RSI)
- INCY 40.69
- WLK 42.86
- Support Level
- INCY $57.05
- WLK $88.78
- Resistance Level
- INCY $59.95
- WLK $91.87
- Average True Range (ATR)
- INCY 2.76
- WLK 5.18
- MACD
- INCY 0.18
- WLK 0.27
- Stochastic Oscillator
- INCY 46.45
- WLK 50.41
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About WLK Westlake Corporation
Westlake Corp is a manufacturer and supplier of chemicals, polymers, and building products. Its Performance and Essential Materials segment offers a wide range of essential building blocks for making products utilized in everyday living, including olefins, vinyl chemicals, polyethylene, and epoxies. Its Housing and Infrastructure Products segment produces key finished goods for building products, pipe and fittings, and global compounds businesses.